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Acute Oral or Dermal and Repeated Dose 90-Day Oral Toxicity
of Tetrasodium Pyrophosphate in Spraque Dawley (SD) Rats
Dong Seok Seo, Min Kwon, Ha Jung Sung, Cheol Beom Park
Hoseo Toxicological Research Center, Hoseo University, Asan, Korea
Objectives: Tetrasodium pyrophosphate (TSP) is used in processed meat products, as an emulsifier in cheese, and as a color preservative in
soybean paste. However, little is known about its toxicity. This study was conducted to investigate the potential acute and repeated dose
toxicity of TSP in Spraque Dawley (SD) rats.
Methods: In the acute study, animals were administered with oral or dermal doses of 2,000 mg/kg TSP. In the repeated dose study, animals
were administered doses of 0, 250, 500, and 1,000 mg/kg by oral gavage five times a week for 90 days. 
Results: In acute toxicity studies, no dead animals or abnormal necropsy findings were found in the control or treated group. In the repeated
dose toxicity study, there were no significant changes in body weight in the 1,000 mg/kg treatment group, or food consumption, urinalysis,
and hematology in any group. With regards serum biochemistry, the levels of total protein, albumin, A/G ratio, triglyceride, calcium and
inorganic phosphate were altered at doses of 500 and 1,000 mg/kg. However, no changes were observed at the dose of 250 mg/kg. With
regards histopathological findings, cortical tubular basophilia of the kidney increased at the dose of 1,000 mg/kg, but not at doses of 250 and
500 mg/kg. No significant changes were observed in other organs at doses of 250, 500, and 1,000 mg/kg.
Conclusions: Based on the results, TSP is unclassified according to the Globally Harmonization System, with an LD50 value of over 2,000
mg/kg. The no observed effect level (NOEL) and no observed adverse effect level (NOAEL) were 250 and 500 mg/kg /day respectively and the
target organ appears to be the kidney.
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INTRODUCTION
Chemicals are constantly being developed and produced
to meet the needs of new applications and components.
There are currently 10 million species of chemicals in
circulation worldwide. Every year 2000 new species are
developed and produced commercially, and continued
growth of the chemical industry is expected. According to
the OECD, the production of chemicals will increase by a
further 80% until 2020 based on the volume produced in
1995.
Tetrasodium pyrophosphate (TSP; CAS No. 7722-88-5) is
a colorless or white crystalline powder, is slightly
efflorescent in air, and is insoluble in ethanol [1-3]. TSP is
used in various fields, with 537 tons manufactured in korea
and 125 tons imported in 2006 [4-6]. The reaction between
the polyphosphate chain and protein was discovered in 1916
[7] and industrial manufacture began in 1920 [8,9]. TSP is
used in processed meat and used as form of the mixture of
tripolyphosphate. Pyrophosphate, glucose, and sorubin acid
are added to fish and sausages. It is also used as a catalyst
and as an emulsifier in cheese [10,11]. It is generally used in
combination with a phosphate or metaphosphate and the
amount used differs according to the pH. Addition of TSP to
soybean paste prevents discoloration , and to soy sauce
becomes well the harmony of colors. It is also used to restrict
the acidification and fermentation of soy sauce owing to its
high alkalinity, and to prevent sedimentation in soft drinks. 
In humans, TSP can cause laryngopharyngitis, coughing,
and breathlessness when inhaled, strong irritation, redness,
pain, and edema following exposure of the skin, and eye
irritation, pain, and blurriness of vision if coming into
contact with the eyes [12]. Various toxicity data for TSP
have recently been reported. The LD50 of rats and mice
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Open Accessorally exposed to TSP was over 2,000 mg/kg body weight
(BW). [13,14]. Mutagenic activity using the Ames test was
negative [15]. However there is little information on dermal
and repeated dose oral exposure toxicity. Therefore we
investigated the potential acute and repeated dose toxicity,
providing useful information for assessing the toxicological
relevance of TSP. Tests were carried out according to the
Ministry of Labor guidelines for testing the hazards and risks
of industrial chemical elements and the OECD guidelines for
testing chemicals, section 4.
MATERIALS AND METHODS
I. Test Substance and Preparation
TSP (Lot No. 048K0049), a colorless white powder, was
chemically synthesized and provided by SIGMA-
ALDRICH (Korea). TSP was dissolved in distilled water
immediately before treatment. Lower doses were prepared
by stepwise dilution of the highest dose.
II. Animal Husbandry and Maintenance
Young adult spraque-dawley (SD) rats (5 weeks old) of
both sexes were purchased from the Orient Bio Co., Ltd.
(Gyeonggi-do, Korea) and acclimated for 6 days prior to
commencement of the studies. The animals were housed in
groups of two to three in stainless steel wire mesh cages and
were allowed sterilized tap water and commercial rodent
chow (2.0 Mrad Ǳ -ray sterilized EP pellet, Cargill Agri
Purina Korea Ltd, Korea). The animals were housed in a
room maintained at a temperature of 233 and a relative
humidity of 555% with artificial lighting from 08:00 to
20:00 and with 10~18 air changes per hour. Only healthy
animals were assigned to the studies. All animals were
maintained in accordance with the Guide for the Care and
Use of Laboratory Animals (Korea Testing and Research
Institute).
III. Acute Oral Toxicity Study
The study was conducted in accordance with OECD
guidelines for the Testing of Chemical No. 420 ‘Fixed dose
method’ [16] and the Notification of the Ministry of Labor
No. 2008-11 ‘Examination of toxic risk about industrial
chemicals’ [17]. Six-week-old female rats (5/group) were
randomly assigned and fasted for approximately 12 hour
prior to dosing. The test substance was formulated as a 200
mg/mL suspension in distilled water then administered to
one animal at a dose of 2,000 mg/kg body weight by oral
gavage; the same procedure was carried out in four animals
for reconfirmation (1st, 2nd step). Each animal was observed
for signs of toxicity at 1 and 3 hours after test substance
administration and once daily thereafter for 14 days.
Mortality and morbidity checks were performed daily. Body
weight was recorded before administration, on day 1 and 7,
and at termination. On day 15, surviving rats were
euthanized, necropsies were performed, and any gross
observations were recorded.
IV. Acute Dermal Toxicity Study
The study was conducted in accordance with the OECD
guidelines for the Testing of Chemical No. 402 ‘Acute
dermal toxicity’ [16] and the Notification of the Ministry of
Labor No. 2008-11 ‘Examination of toxic risk about
industrial chemicals’ [17]. Twenty rats (160-220 g) were
randomly assigned. The test substance was formulated as a
400 mg/mL suspension in distilled water then administered to
each animal at the dose of 2,000 mg/kg BW. The fur on the
back of each animal was closely clipped 24 hour before
treatment. The test substance was directly applied to a small
area (4 cm-5 cm) of skin. After application of the test
substance, the test area was covered with a non-occlusive
dressing (a gauze patch) and then a semi-occlusive bandage
for 24 hour. At the end of the exposure period, any residual
test substance was removed by distilled water, and carefully
dried. Each animal was observed for signs of toxicity once
daily for 14 days following treatment. Mortality and
morbidity checks were performed daily. Body weight was
recorded before treatment, on day 1 and 7, and at termination.
On day 15, surviving rats were euthanized, necropsies were
performed, and any gross observations were recorded.
V. Repeated Dose 90-Day Oral Toxicity Study
A repeated dose 90-day oral toxicity study was conducted
in accordance with OECD guidelines for the Testing of
Chemical No. 408 ‘Repeated Dose 90-day Oral Toxicity
Study in Rodents’ [16] and the notification of the Ministry of
Labor No. 2008-11 ‘Examination of Toxic Risk about
Industrial Chemicals’ [17]. Groups of 10 randomly assigned
rats (6 weeks old) of each sex were injected by oral gavage
with TSP suspended in distilled water at doses of 250, 500,
and 1,000 mg/kg/BW/day five times a week for 90 days.
The doses were selected based on the results of the acute
toxicity study and a 14-day dose range study. No toxicity or
mortality was observed in any of the five male and female
rats treated with TSP for 14 days. The control groups
received vehicle (filtered tap water) only.
VI. Mortality and Clinical Signs
All animals were observed thoroughly for the onset of any
immediate signs of toxicity, and throughout the observation period
to record any delayed acute effects and mortality. All animals were
observed once a day for 90 days after administration.
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All animals were monitored for BW changes once a week
after administration. The mean BW of animals that survived
up to the end of the administration period (90 days) was
calculated. Food consumption by each group was measured
at the start of treatment and during the 90-day administration
period.
VIII. Urinalysis
During the last week of administration, urinalysis of five
animals of each sex per group was conducted to determine
glucose, bilirubin, ketone body, specific gravity, blood, pH,
protein, urobilinogen, nitrite and leukocyte levels, using the
Multistix 10SG (Bayer, U.S.A.) and urine analyzer (Clinitek
500, U.S.A.).
IX. Hematology and Coagulation
Animals were fasted overnight and, following isoflurane
inhalation anesthesia, blood samples for hematology and
clinical chemistry were collected from the abdominal aorta
using a syringe and a 24-gauge needle. Hematology
parameters in EDTA 3K-treated blood (Sewon Medical,
Korea) were measured using a hematological autoanalyzer
(Advia 120E, Bayer, UK), including total white blood cell
(WBC) count, differential leukocyte percentage, total red
blood cell (RBC) count, hemoglobin (Hb) concentration,
hematocrit (Hct), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), reticulocyte ratio
(Retic), and platelet count (PLT). Prothrombin time (PT) and
activated partial thromboplastin time (APTT) were
measured in sodium citrate-treated blood using an automated
hematocoagulation analyzer (Coagrex-100S, Japan). 
X. Biochemistry 
Blood collected for serum biochemistry was untreated and
centrifuged at 3,000 rpm for 10 minutes. The serum obtained
was examined for the following parameters using a
biochemistry autoanalyzer (Hitachi 7060, Japan): total
protein (TP), albumin (ALB), A/G ratio, total bilirubin (T-
BIL), alkaline phosphatase (ALP), aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), creatinine
(CRN), blood urea nitrogen (BUN), total cholesterol
(CHOL), triglycerides (TG), glucose (GLU), calcium (Ca),
phosphorus (IP) and creatine kinase (CK). Serum electrolytes
such as chloride (Cl), sodium (Na), and potassium (K) were
measured using an ion autoanalyzer (Bayer 644 Na/K/Cl
analyzer, USA).
XI. Necropsy Findings
At scheduled termination, all surviving animals were
anesthetized by isoflurane inhalation for blood sample
collection, and then sacrificed by exsanguination of the
abdominal aorta. Complete gross postmortem examinations
were performed on all terminated animals. All organs were
fixed and stored individually for histopathological
examination. 
XII. Organ Weights
The absolute and relative (organ-to-BW ratios) weights of
the following organs were measured in all survivors
following sacrifice: liver, kidneys, adrenals, testis, ovaries,
and brain.
XIII. Histopathology
The following tissues were obtained from all animals:
brain, pituitary, eye, thyroids, heart, lung, liver, kidney,
spleen, adrenals, stomach, testis, urinary bladder, femur, and
ovaries. Eyes and testes were preserved in Davidson’s
fixative and Bouin’s fixative, respectively. Other tissues
were fixed with 10% neutral buffered formalin solution. The
liver, kidney, adrenal, heart, and spleen from the high dosage
and control groups were routinely processed, embedded in
paraffin, and sectioned to 3-5 Ǻ m. The sections were stained
with hematoxylin and eosin for microscopic examination. 
XIV. Statistical Analysis
The GHS class in the acute toxicity test was calculated
according to the OECD guideline 420 [16]. The results are
presented as the mean  standard deviation (SD). The
differences in parameters (BWs, organ weights, and the
results of the blood biochemistry and hematology) between
groups in the acute and sub-chronic toxicity test were
assessed by a standard two-way analysis of variance
(ANOVA). If these showed statistical significance,
Duncan’s or Dunnett’s multiple range test were used to
compare groups (SPSS version 12.0 [SPSS Inc., Chicago,
IL, USA]). P-values < 0.05 were considered statistically
significant.
RESULTS
I. Acute Oral/Dermal Toxicity Study
There were no dead animals, clinical signs, or necropsy
findings in rats administered with 2,000 mg/kg of TSP via
the oral or dermal route (data not shown). 
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A) Mortality and clinical signs
There was no treatment-related mortality in the animals
treated with the test substance during the study. Female rats
treated with 500 and 1,000 mg/kg of test substance showed
hair loss. No significant clinical signs were observed in any
other group.
B) Body weight
The terminal body weight of male rats treated with 1,000
mg/kg of test substance was lower than that of the control
group, while there were no differences in body weight
between the 250, 500 mg/kg, and control group. There was
no treatment-related change in body weight in female rats
(Figure 1,2). 
C) Food consumption
A significant decrease in food consumption was observed
in the 1,000 mg/kg group of males at week 8 and 9. Food
consumption in females increased significantly in the 1,000
mg/kg group at week 4. There were no significant changes
in food consumption in the other groups (Table 1).
D) Urinalysis and hematology
There were no specific symptoms in urinalysis at the doses
of 250, 500, and 1,000 mg/kg. There were no significant
changes in hematology in the 250 mg/kg group. 
WBC and neutrophil counts were significantly increased
in males and females of the 1,000 mg/kg group, whereas the
lymphocyte count was significantly lower in males and
females of the 1,000 mg/kg group. RBC, HB, HCT, PT, and
APTT were significantly reduced in the males of the 1,000
mg/kg group, and PT was significantly reduced in males of
the 500 mg/kg group (Table 2). 
E) Biochemistry
There were no significant changes in the serum
biochemistry of males and females in the 250 mg/kg group.
Total protein was significantly reduced in both sexes in
the 500 and 1,000 mg/kg group. Albumin was significantly
reduced in males of the 500 and 1,000 mg/kg group, and in
females of the 1,000 mg/kg group. The A/G ratio was
significantly increased in females of the 500 and 1,000
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Figure 1.Changes in body weight of male rats orally treated with tetrasodium pyrophosphate for 90 days.
Figure 2.Changes in body weight of female rats orally treated with tetrasodium pyrophosphate for 90 days.mg/kg group. T-BIL was significantly increased in females
of the 1,000 mg/kg group, and ALP was significantly
reduced in females of the 1,000 mg/kg group. AST was
significantly increased in males of the 1,000 mg/kg group,
but ALT was significantly reduced in females of the 1,000
mg/kg group. TG were significantly increased in both sexes
in the 1,000 mg/kg group, while Ca, IP, Na, K, and Cl were
significantly reduced in both sexes in this group. IP was also
reduced in males of the 500 mg/kg group (Table 3). 
F) Necropsy findings and organ weight
There were no grossly visible findings or lesions in any
group. There were no significant changes in organ weight in
males and females of the 250 mg/kg group. The relative
weight of the liver in the males of the 500 mg/kg and 1,000
mg/kg groups showed a significant increase. The absolute
and relative weight of the liver in females of the 500 mg/kg
and 1,000 mg/kg groups were also significantly increased
(Table 4,5). 
G) Histopathology
No exposure-related histopathological changes were
observed in any of the organs examined in SD rats, with the
exception of kidney lesions. Cortical tubular basophilia of
the renal tubule was more evident in males of the 1,000
mg/kg group and mineralization of the kidney was evident in
females of the 1,000 mg/kg group. Other background lesions
were observed in the 0, 250, 500, and 1,000 mg/kg groups in
both sexes (Table 6). 
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Table 1.Food consumption of SD rats orally treated with tetrasodium pyrophosphate for 90 days
Week
Male
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Female
1
2
3
4
5
6
7
8
9
10
11
12
13
*p<0.05, 
õp<0.01.
27.1  1.0 
30.4  0.9 
33.8  1.9 
30.9  1.2 
33.4  2.8 
29.3  3.9 
33.1  2.7 
31.5  2.1 
31.8  2.1 
32.7  2.0 
29.8  2.7 
33.8  0.5 
30.1  2.2 
27.0  1.6 
28.5  6.4 
34.1  2.2 
31.6  2.5 
30.8  1.2 
27.9  2.6 
33.3  2.6 
31.3  2.1 
31.2  1.7 
31.6  2.3 
30.3  3.0 
33.5  0.5 
29.4  2.3 
26.7  0.9 
30.7  1.7 
32.9  3.1 
31.8  6.6 
31.8  2.7 
29.2  1.9 
33.8  1.2 
33.0  1.6 
30.5  1.1 
31.9  1.1 
29.6  2.0 
33.2  0.6 
31.2  1.8 
27.1  1.8 
29.2  1.4 
30.4  3.6
28.5  3.2 
30.5  2.1 
27.9  2.9 
32.9  3.2 
28.3  0.5
õ
28.2  2.5*
28.8  1.8 
27.8  1.6 
33.4  0.5 
28.5  1.7 
19.1  1.4 
21.1  2.6 
22.6  2.2 
19.7  2.5 
21.7  0.6 
18.1  2.0 
24.3  2.0 
20.8  2.0 
20.6  3.8 
21.2  1.3 
20.5  3.5 
20.2  1.8 
20.1  1.5 
20.6  1.7 
21.3  3.9 
22.6  2.7 
20.5  1.4 
20.3  3.3 
17.1  3.7 
21.9  2.0 
20.3  2.9 
18.8  2.7 
18.9  3.8
19.5  2.3 
19.7  3.1 
18.6  1.9 
19.9  1.5 
21.4  2.1 
21.8  2.1 
21.3  1.5 
19.3  2.5 
18.2  1.8 
23.2  2.8 
21.7  2.8 
19.9  1.4 
21.2  2.4 
21.1  3.7 
21.5  2.0 
20.4  3.6 
20.2  1.0 
20.3  2.1 
21.7  1.0 
22.7  1.3*
22.9  2.7 
19.2  1.3 
23.9  2.9 
21.0  2.2 
19.8  2.1 
19.4  1.7 
21.0  3.9 
20.3  2.9 
21.1  2.5 
Table 2.Hematological values of SD rats orally treated with tetrasodium pyrophosphate for 90 days
Items
Male
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Female
WBC (K)
Neutrophil (%)
Lymphocyte (%)
Monocyte (%)
Eosinophil (%)
Basophil (%)
RBC (M)
Hb (g/dl)
Hct (%)
MCV (fL)
MCH (pg)
MCHC (g/dL)
Reticulocyte (%)
PLT (K)
PT (sec)
APTT (sec)
WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Hct: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin , MCHC:
mean corpuscular hemoglobin concentration, PLT: platelet. PT: prothrombin time, APTT: activated partial thromboplastin time.
*p<0.05, 
õp<0.01.
7.20  1.830 
14.2  4.600 
80.1  4.500 
3.6  1.100 
1.4  0.500 
0.2  0.100 
8.56  0.190 
15.3  0.500  
45.5  1.400 
53.1  1.100 
17.9  0.400 
33.8  0.500 
2.04  0.340 
1148.2  124.4 
17.7  0.500 
20.3  1.200 
6.62  0.71 
18.6  6.20 
74.8  6.20 
3.9  1.60 
1.9  0.50 
0.2  0.10 
8.43  0.34 
14.9  0.70 
44.3  1.80 
52.5  1.30 
17.6  0.50 
33.5  0.50 
2.1  0.30 
1071.6  98.4 
17.6  0.60 
19.5  1.90 
7.76  1.580 
20.1  6.600 
73.6  6.900 
3.4  1.100
2.3  0.7*0
0.2  0.100
8.55  0.420
14.8  0.800
44.4  2.200
52.0  2.700
17.3  1.000
33.2  0.600
2.38  0.520
1213.9  123.4 
16.7  0.6
õ0
19.4  1.200
9.35  1.31* 
24.8  4.900
68.7  6.000
4.1  1.800
1.8  0.600
0.3  0.100
8.19  0.19
õ
14.4  0.3
õ0
43.1  0.8
õ0
52.7  0.900
17.6  0.400
33.4  0.500
2.37  0.380
1264.5  110.5 
16.5  0.6
õ0
18.4  1.1*0
3.72  1.860
12.2  3.700
81.4  5.000
3.6  1.500
2.1  0.900
0.2  0.100
7.82  0.280
14.4  0.500
42.3  1.500
54.1  1.200
18.5  0.500
34.1  0.400
1.79  0.410
1153.7  171.4 
16.9  0.800
16.4  0.800
6.84  2.090
17.7  5.000
74.4  6.100
3.7  0.200
1.9  0.300
0.2  0.000
8.16  0.400
14.5  0.600
43.1  2.000
52.0  2.400
17.5  0.900
33.0  1.400
2.11  0.260
1153.2  105.1 
17.1  0.600
18.8  1.500
4.44  0.660
17.3  7.300
75.4  7.400
3.8  1.700
2.6  1.100
0.2  0.100
7.96  0.230
14.6  0.400
42.8  1.300
53.8  1.300
18.3  0.500
34.1  0.200
2.02  0.490
1169.5  427.3 
17.1  1.000
16.5  0.900
6.39  1.83
õ
20.9  6.3*0
73.2  7.0*0
3.3  0.900
2.1  0.600
0.2  0.100
7.82  0.250
14.1  0.400
42.0  1.200
53.7  0.900
18.1  0.200
33.7  0.400
2.27  0.420
1441.4  210.2 
16.4  0.900
16.7  0.800DISCUSSION
No acute toxicity of TSP was observed at the dose of
2,000 mg/kg. No abnormal clinical signs were observed
following acute oral or dermal administration of TSP. In the
repeated dose toxicity study, significantly differences in
parameters were observed such as body weight,
hematological and serum biochemical analysis and
histopathological lesions at the medium and high doses of
TSP. TSP may be toxic to humans when exposed orally or
via inhalation [12]. According to acute oral toxicity studies,
the LD50 in rats is over 2,000 mg/kg BW [18] and the
dermal LD50 in rabbits is 7,940 mg/kg [18]. Dermal
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6of 9 pages
Table 3.Biochemical values of SD rats orally treated with tetrasodium pyrophosphate for 90 days
Items
Male
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Female
TP (g/dL)
Albumin (g/dL)
A/G ratio (ratio)
T-BIL (mg/dL)
ALP (U/L)
AST (U/L)
ALT (U/L)
CRN (mg/dL)
BUN (mg/dL)
CHOL (mg/dL)
TG (mg/dL)
GLU (mg/dL)
Ca (mg/dL)
IP (mg/dL)
CK (IU/L)
Na (mmol/L)
K (mmol/L)
Cl (mmol/L)
TP: total protein, T-BIL: total bilirubin, ALP: alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, CRN: creatinine, 
BUN: blood urea nitrogen , CHOL: total cholesterol, TG: triglycerides, GLU: glucose, Ca: calcium, IP: phosphorus, CK: creatine kinase, Na: sodium, 
K: potassium, Cl: chloride.
*p<0.05, 
õp<0.01.
6.2  0.400
2.5  0.200
0.67  0.050
0.078  0.010 
270  49.00
99  21.00
35  5.000
0.6  0.000
11.5  1.400
71  14.00
118  29.00
143  21.00
10.0  0.200
7.3  0.400
354  221.0
142  2.000
4.6  0.300
107  2.000
6.0  0.200
2.4  0.100
0.68  0.060
0.071  0.010 
278  36.00
117  20.00
37  10.00
0.6  0.000
11.5  2.200
67  8.000
106  38.00
138  15.00
9.9  0.300
6.7  0.500
504  233.0 
141  2.000
4.6  0.100
108  1.000
5.4  0.3
õ0
2.3  0.1*0
0.73  0.020
0.074  0.015 
277  74.00
103  16.00
31  4.000
0.6  0.000
12.2  1.300
78  19.00
178  68.00
139  24.00
9.7  0.400
6.4  0.5
õ0
449  268.0 
140  2.000
4.6  0.200
106  2.000
4.8  0.3
õ0
2.1  0.1
õ0
0.74  0.05* 
0.076  0.031 
227  55.00
138  25.0
õ
39  13.00
0.6  0.100
13.6  1.700
75  11.00
183  57.0*
132  14.00
9.2  0.3
õ0
5.7  0.4
õ0
617  1810.
139  1.000
4.2  0.3*0
103  3.0*0
6.7  0.300
3.0  0.200
0.78  0.060
0.104  0.010 
146  40.00
113  32.00
28  7.000
0.7  0.100
12.8  2.600
78  18.00
25  17.00
143  26.00
10.1  0.400
6.1  0.600
533  259.0
142  1.000
4.3  0.200
107  1.000
6.5  0.300
2.9  0.200
0.84  0.050
0.096  0.013 
139  35.00
128  50.00
39  28.00
0.7  0.100
14.3  1.700
81  16.00
39  22.00
137  13.00
10.0  0.300
6.1  0.800
556  203.0
141  1.000
4.2  0.200
106  1.000
5.8  0.5
õ0
2.7  0.200
0.88  0.06* 
0.083  0.017 
118  23.00
109  25.00
24  4.000
0.7  0.000
12.8  1.700
79  12.00
91  68.00
128  8.000
9.7  0.200
5.6  0.400
569  433.0 
140  1.0
õ0
4.3  0.200
105  1.000
4.9  0.3
õ0
2.3  0.2
õ0
0.87  0.06* 
0.075  0.024
õ
103  26.0*
110  25.00
17  1.0
õ0
0.7  0.100
11.8  1.800
74  8.000
141  96.0* 
135  18.00
9.0  0.2
õ0
4.7  0.4*0
612  318.0
139  2.0
õ0
4.0  0.300
105  2.000
Table 4.Absolute organ weights of SD rats orally treated with tetrasodium pyrophosphate for 90 days
Organs (g)
Male
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Female
Liver
Kidney left
Kidney right
Adrenal gland left
Adrenal gland right
Testis/ovary left
Testis/ovary right
Brain
*p<0.01.
14.54  1.240
1.77  0.150
1.70  0.190
0.036  0.008 
0.035  0.004 
1.76  0.130
1.76  0.110
2.14  0.090
14.26  2.170
1.76  0.230
1.74  0.200
0.029  0.004 
0.032  0.004 
1.76  0.130
1.73  0.130
2.10  0.120
16.28  2.550
1.82  0.170
1.82  0.200
0.031  0.005 
0.030  0.004 
1.74  0.150
1.73  0.140
2.10  0.080
14.53  1.590
1.69  0.190
1.72  0.180
0.035  0.006 
0.031  0.004 
1.70  0.110
1.71  0.110
2.07  0.110
7.33  0.830
0.99  0.130
1.00  0.090
0.032  0.007 
0.033  0.007 
0.041  0.011 
0.043  0.011 
1.96  0.100
7.25  0.870
0.97  0.070
0.89  0.320
0.034  0.003 
0.034  0.005 
0.041  0.013 
0.043  0.008 
1.95  0.130
8.09  0.600
1.02  0.070
1.05  0.060
0.033  0.007 
0.034  0.006 
0.043  0.009 
0.044  0.006 
1.95  0.110
9.06  1.09
õ
1.06  0.100
1.08  0.120
0.036  0.005 
0.037  0.009 
0.046  0.008 
0.045  0.008 
1.97  0.110
Table 5.Relative organ weights of SD rats orally treated with tetrasodium pyrophosphate for 90 days
Organs (g)
Male
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Female
Liver
Kidney left
Kidney right
Adrenal gland left
Adrenal gland right
Testis/Ovary left
Testis/Ovary right
Brain
*p<0.05, 
õp<0.01.
2.50  0.160
0.30  0.030
0.31  0.030
0.006  0.001 
0.006  0.001 
0.30  0.020
0.30  0.010
0.37  0.030
2.53  0.180
0.31  0.020
0.31  0.020
0.005  0.001 
0.006  0.001 
0.32  0.040
0.31  0.040
0.38  0.040
2.76  0.17* 
0.32  0.030
0.32  0.010
0.005  0.001 
0.006  0.001 
0.30  0.040
0.30  0.050
0.37  0.040
2.80  0.17* 
0.33  0.030
0.33  0.030
0.007  0.001 
0.006  0.001 
0.33  0.040
0.33  0.040
0.40  0.030
2.41  0.100
0.33  0.040
0.33  0.020
0.010  0.002 
0.011  0.002 
0.014  0.004 
0.014  0.003 
0.65  0.080
2.42  0.100
0.33  0.040
0.30  0.110
0.011  0.002 
0.012  0.002 
0.014  0.004 
0.015  0.003 
0.66  0.090
2.81  0.18
õ
0.35  0.030
0.36  0.020
0.011  0.003 
0.012  0.002 
0.014  0.003 
0.014  0.001 
0.65  0.050
2.94  0.25
õ
0.34  0.040
0.35  0.040
0.012  0.001 
0.012  0.003 
0.015  0.003 
0.015  0.003 
0.64  0.050administration of TSP at doses of up to 2,000 mg/kg showed
no signs of toxicity. 
In the repeated dose study, body weight and terminal BW
were reduced compared to controls in males of the 1,000
mg/kg group, but not the females. However, females of the
500 mg/kg group showed a slight reduction in BW,
suggesting that TSP affects the BW of female rats at doses
of over 1,000 mg/kg.
Food consumption varied temporally in a dose-
independent manner, with significant changes in some
groups. The increase in WBCs such as neutrophil suggests
that there was an inflammatory reaction to TSP
administration, but microscopically there was no neutrophil
infiltration of the target organ. A decrease in RBC-related
parameters indicates anemia, but there was no clinical sign
of this, and the level of parameters were on normal
physiological change level of rat. So there was no evidence
that TSP induces anemia in rats at the dose of 1,000 mg/kg.
PT and APTT were also reduced, but the level of parameters
was on background data level of normal rat and was
biologically meaningless things. Therefore, TSP had no
toxic effect on the hematological parameters of SD rats at
the dose of 1,000 mg/kg. 
TP and albumin decreased in this experiment, which may
be related to the reduction in BW [19]. A decrease in BW
may be related to malnutrition, the lack of vitamins, and a
decrease in body electrolytes [20,21]. So it maybe adopt
change according to the BW change, and it is toxicologically
meaningless things. T-BIL and ALP were also reduced in
females of the 1,000 mg/kg group, and may be linked to the
kidney lesions. The males of the 1,000 mg/kg group showed
a tendency for a reduction in these parameters. This explains
why kidney lesions were more common in the high dose
group. Therefore, these changes of T-BIL and ALP were
related to toxicity to the kidney at the dose of 1,000 mg/kg
TSP. AST and relative liver organ weight showed an
increase in males of the 1,000 mg/kg group, while AST
showed no increase and ALT was reduced in females of the
1,000 mg/kg group. Microscopic examination found no
obvious liver lesions associated with TSP treatment, which
means that TSP treatment had no effect on AST or ALT. TG
was increased in both sexes in the 1,000 mg/kg group, but it
is temporally meaningless change. Decrease of Ca, IP and
Na at dose of 1000 mg/kg group and the level of those
parameters were on background data of normal rat. 
An increase of liver organ weight was usually
accompanied by a decrease in BW. However the liver
weight of females receiving the 1,000 mg/kg dose increased
without a decrease in BW. 
Tubular basophilia of the renal tubule was evident in
males and females, with mineralization of the kidney in
females. Tubular basophilia is a relatively frequent finding in
young control rats [22], and can be induced by nephrotoxic
agents; the lesion is regenerative in nature. L-cystein induced
tubular basophilia at the dose of 1000 mg/kg after 4 weeks
of administration in rats [23], and methotrexate caused an
increase in tubular basophilia in mice [24]. The high
incidence of tubular basophilia showed that the target organ
90-Day Oral Toxicity of Tetrasodium Pyrophosphate
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Table 6.Incidence of histopathological findings in SD rats orally treated with tetrasodium pyrophosphate for 90 days          (n=10)
Findings
Male Female
Group 1  Group 2 Group 3  Group 4  Group 1  Group 2 Group 3  Group 4 
Liver 
Centrilobular vacuolation
Periportal vacuolation
Parenchymal degeneration
Kidney
Cortical tubular basophilia
Medullary tubular basophilia
Interstitial inflammatory cells
Cortical mineralization
Medullary mineralization
Medullary cyst
Papillary epithelial hyperplasia
Cortical scarring
Transitional epithelial hyperplasia
Pelvic transitional epithelial Inflammatory cells
Adrenal gland
Cortical vacuolation
Hypertrophy-zona glomerulosa
Cortical cyst
Heart
Myocardial inflammatory cells
Myocardial fibrosis
Spleen
Extramedullary hematopoiesis
0
0
0
3
0
2
0
0
2
0
0
0
0
4
0
0
1
2
1
0
0
0
3
0
3
0
0
0
1
0
0
0
7
0
0
8
1
1
1
0
0
3
0
1
0
0
0
0
2
2
0
5
1
0
6
3
1
0
0
0
7
0
0
0
0
0
0
0
0
1
2
0
1
5
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
2
0
0
0
0
0
0
0
0
2
0
0
0
2
0
6
0
0
3
9
0
0
0
0
0
1
0
0
0
4
0of TSP may be the kidney. Focal mineralization of renal
tubules is a frequent finding in the rat [25]. In one report,
100% of female Wistar rats, but no males, exhibited the
lesion. Cam deposits may be induced in female rats by
administering estrogen [26]. Thus female hormones may
have some effect on mineralization of the renal tubule. The
results in females in the current study were similar to
previous research on another chemical, in which
mineralization was increased compared to the control,
meaning that TSP may be related to mineralization toxicity
in females [26]. Pyrophosphate is a potent inhibitor of
vascular calcification [27], however for its tetrasodium salt,
TSP induced renal mineralization. Thus it is future
investigation whether TSP was inhibitor of vascular
calcification or not. 
In summary, T-BIL and ALP decreased, and tubular
basophilia of the kidney increased in both sexes at the dose
of 1,000 mg/kg, while mineralization increased in females at
this dose. Hematological parameters such as TP, ALB, A/G
ratio, AST, IP and Na showed significant changes in males
and females of the 500 mg/kg and 1000 mg/kg groups, but
these may not have been toxicological changes. 
Based on these results, the no observed effect level
(NOEL) and no observed adverse effect level (NOAEL)
were considered to be 250 and 500 mg/kg /day respectively
under the conditions of this study.
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